Approaches of surgical and complex treatment of patients with gastrointestinal stromal tumours
Abstract
Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of gastrointestinal tract. There are two main options for GIST's treatment: surgical treatment and targeted
therapy. Surgical treatment remains the cornerstone of treatment for patients with localized
disease. Combination of surgical treatment and targeted therapy allows to improve long-term
results of treatment for locally advanced and metastatic tumors.
Keywords:gastrointestinal stromal tumors, surgical treatment, targeted therapy
Clin. Experiment. Surg. Petrovsky J. 2017; 5 (4): 85–91.
DOI: 10.24411/2308-1198-2017-00012
Received: 15.09.2017. Accepted: 10.10.2017.
References
1. Nilsson B., Bumming P., Meis-Kindblom J.M., et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course,
and prognostication in the preimatinib mesylate era – a population-
based study in western Sweden. Cancer. 2005; 103 (4): 821–9.
2. Joensuu H., Hohenberger P., Corless C.L. Gastrointestinal
stromal tumour. Lancet. 2013; 382: 973–83.
3. Kekeeva T.V., Zavalishina L.E., Andreeva Yu.Yu., et al. Analysis
of the mutations of the kit gene in gastrointestinal stromal tumours.
Rossiyskiy onkologicheskiy zhurnal [Russian Journal of Cancer].
2009; (5): 23–8. (in Russian)
4. Lux M.L., Rubin B.P., Biase T.L., et al. KIT extracellular and
kinase domain mutations in gastrointestinal stromal tumors. Am
J Pathol. 2000; 156 (3): 791–5.
5. Corless C.L., Schroeder A., Griffith D., et al. PDGFRA mutations
in gastrointestinal stromal tumors: frequency, spectrum and in vitro
sensitivity to imatinib. J Clin Oncol. 2005; 23: 5357–64.
6. Corless C.L., Fletcher J.A., Heinrich M.C. Biology of gastrointestinal stromal tumors. J Clin Oncol. 2004; 22: 3813–25.
7. Agaram N.P., Wong G.C., Guo T., et al. Novel V600E BRAF
mutations in imatinib-naive and imatinib-resistant gastrointestinal
stromal tumors. Genes Chromosomes Cancer. 2008; 47: 853–9.
8. Miranda C., Nucifora M., Molinari F., et al. KRAS and BRAF
mutations predict primary resistance to imatinib in gastrointestinal
stromal tumors. Clin Cancer Res. 2012; 18 (6): 1769–76.
9. Kopp M.V., Koroleva I.A. Multidisciplinary approach
in the diagnosis and treatment of gastrointestinal stromal tumours.
Zlokachestvennye opukholi [Journal of Malignant Tumours ] 2013;
(1): 15–27. (in Russian)
10. Demetri G.D., von Mehren M., Antonescu C.R., et. al. NCCN
Task Force report: update on the management of patients with
gastrointestinal stromal tumors. J Natl Compr Canc Netw. 2010;
8 (2): 1–41.
11. Frankel T.L., Chang A.E., Wong S.L. Surgical options for
localized and advanced gastrointestinal stromal tumors. J Surg
Oncol. 2011; 104: 882–7.
12. DeMatteo R.P., Lewis J.J., Leung D., et al. Two hundred
gastrointestinal stromal tumors: recurrence patterns and prognostic
factors for survival. Ann Surg. 2000; 231 (1): 51–8.
13. Casper E.S. Gastrointestinal stromal tumors. Curr Treat
Options Oncol. 2000; 1 (3): 267–73.
14. Quek R., George S. Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib. Biologics Targets Ther.
2010; 4: 19–31.
15. Dematteo R.P., Ballman K.V., Antonescu C.R., et al.
Adjuvant imatinib mesylate after resection of localised, primary
gastrointestinal stromal tumour: a randomised, double-blind,
placebo-controlled trial. Lancet. 2009; 373: 1097–104.
16. The ESMO/European Sarcoma Network Working Group.
Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines
for diagnosis, treatment and follow-up. Ann Oncol. 2014;
25 (3): 21–6.
17. Gouveia A.M., Pimenta A.P., Capelinha A.F., et al. Surgical
margin status and prognosis of gastrointestinal stromal tumor. World
J Surg. 2008; 32: 2375–82.
18. McCarter M.D., Antonescu C.R., Ballman K.V., et al.
Microscopically positive margins for primary gastrointestinal stromal
tumors: analysis of risk factors and tumor recurrence. J Am Coll Surg.
2012; 215 (1): 53–9.
19. Hohenberger P., Ronellenfitsch U., Oladeji O., et al. Pattern
of recurrence in patients with ruptured primary gastrointestinal
stromal tumour. Br J Surg. 2010; 97: 1854–9.
20. Reichardt P., Blay J.Y., Boukovinas I., et al. Adjuvant
therapy in primary GIST: state-of-the-art. Ann Oncol. 2012;
23: 2776–81.
21. Goh B.K., Chow P.K., Chok A.Y., et al. Impact of the
introduction of laparoscopic wedge resection as a surgical option
for suspected small/medium-sized gastrointestinal stromal tumors
of the stomach on perioperative and oncologic outcomes. World
J Surg. 2010; 34: 1847–52.
22. Matthews B.D., Walsh R.M., Kercher K.W., et al. Laparoscopic
vs open resection of gastric stromal tumors. Surg Endosc. 2002;
16 (5): 803–7.
23. Nguyen N.T., Jim J., Nguyen A., et al. Laparoscopic
resection of gastric stromal tumor: a tailored approach. Am Surg.
2003; 69: 946–50.
24. Fiore M., Palassini E., Fumagalli E., et al. Preoperative
imatinib mesylate for unresectable or locally advanced primary
gastrointestinal stromal tumors (GIST). Eur J Surg Oncol. 2009;
35: 739–45.
25. Blesius A., Cassier P.A., Bertucci F., et al. Neoadjuvant
imatinib in patients with locally advanced non metastatic GIST
in the prospective BFR14 trial. BMC Cancer. 2011; 11: 72.
26. Rutkowski P., Gronchi A., Hohenberger P., et al. Neoadjuvant
imatinib in locally advanced gastrointestinal stromal tumors (GIST):
the EORTC STBSG experience. Ann Surg Oncol. 2013; 20: 2937–43.
27. Haller F., Detken S., Schulten H.J., et al. Surgical
management after neoadjuvant imatinib therapy in gastrointestinal
stromal tumours (GISTs) with respect to imatinib resistance
caused by secondary KIT mutations. Ann Surg Oncol. 2007; 14 (2):
526–32.
28. Joensuu H., Vehtari A., Riihimaki J., et al. Risk of recurrence
of gastrointestinal stromal tumour after surgery: an analysis
of pooled population-based cohorts. Lancet Oncol. 2012; 13 (3):
265–74.
29. Eisenberg B.L., Harris J., Blanke C.D., et al. Phase II trial
of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced
primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol.
2009; 99 (1): 42–7.
30. Mussi C., Ronellenfitsch U., Jakob J., et al. Post-imatinib
surgery in advanced/metastatic GIST: is it worthwhile in all patients?
Ann Oncol. 2010; 21 (2): 403–8.
31. Sym S.J., Ryu M.H,, Lee J.L., et al. Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs). J Surg Oncol. 2008; 98 (1): 27–33.
32. Gold J.S., van der Zwan S.M., Gonen M., et al. Outcome
of metastatic GIST in the era before tyrosine kinase inhibitors. Ann
Surg Oncol. 2007; 14 (1): 134–42.
33. Blanke C.D., Demetri G.D., von Mehren M., et al. Long-term
results from a randomized phase II trial of standard — versus higher-
dose imatinib mesylate for patients with unresectable or metastatic
gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008;
26 (4): 620–5.
34. Le Cesne A., Van Glabbeke M., Verweij J., et al. Absence
of progression as assessed by response evaluation criteria in solid
tumors predicts survival in advanced GI stromal tumors treated with
imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial.
J Clin Oncol. 2009; 27: 3969–74.
35. Demetri G.D., von Mehren M., Blanke C.D., et al. Efficacy
and safety of imatinib mesylate in advanced gastrointestinal stromal
tumors. N Engl J Med. 2002; 347: 472–80.
36. Gervaz P., Huber O., Morel P. Surgical management
of gastrointestinal stromal tumours. Br J Surg. 2009; 96 (6): 567–78.
37. Raut C.P., Posner M., Desai J., et al. Surgical management
of advanced gastrointestinal stromal tumors after treatment with
targeted systemic therapy using kinase inhibitors. J Clin Oncol.
2006; 24: 2325–31.
38. DeMatteo R.P., Maki R.G., Singer S., et al. Results of tyrosine
kinase inhibitor therapy followed by surgical resection for metastatic
gastrointestinal stromal tumor. Ann Surg. 2007; 245 (3): 347–52.